David Sutton

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 372 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 254 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

M R Boyd, T. H. Bacon, David Sutton et al. · Antimicrobial Agents and Chemotherapy · 1987 · 238 citations

Life Sciences, Infectious Diseases, Microbiology +14

Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]

R. Anthony Vere Hodge, David Sutton, M R Boyd et al. · Antimicrobial Agents and Chemotherapy · 1989 · 210 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12